Pre-made Iratumumab benchmark antibody ( Whole mAb, anti-TNFRSF8 therapeutic antibody, Anti-CD30/Ki-1/D1S166E Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Iratumumab biosimilar, Whole mAb, Anti-TNFRSF8 Antibody: Anti-CD30/Ki-1/D1S166E therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-278-1mg	1mg	3090
GMP-Bios-ab-278-10mg	10mg	Inquiry
GMP-Bios-ab-278-100mg	100mg	Inquiry
GMP-Bios-ab-278-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Iratumumab biosimilar, Whole mAb, Anti-TNFRSF8 Antibody: Anti-CD30/Ki-1/D1S166E therapeutic antibody
INN Name	Iratumumab
Target	TNFRSF8
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2005
Year Recommended	2006
Companies	Medarex
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Hodgkin's disease;Lymphoma;Non-Hodgkin's lymphoma
Development Tech	Medarex UltiMAb Mouse